Hormone replacement therapy and the endometrium

Journal of Clinical Pathology

Volumn 54, Issue 6, 2001, Pages 435-440

  Feeley, K M ^a   Wells, M ^b  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Endometrial carcinoma; Endometrial hyperplasia; Endometrium; Hormone replacement therapy

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; LEVONORGESTREL; NORETHISTERONE ACETATE; PROGESTERONE;

ARTICLE; CANCER RISK; CELL PROLIFERATION; CLINICAL TRIAL; CORRELATION FUNCTION; DECIDUA; DISEASE ASSOCIATION; ENDOMETRIUM; ENDOMETRIUM ATROPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; MENSTRUAL CYCLE; PREVALENCE; PRIORITY JOURNAL;

BIOPSY; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; PRECANCEROUS CONDITIONS; PROGESTINS;

EID: 0034994194     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.54.6.435     Document Type: Article

References (75)

1. Use of HRT and the subsequent risk of cancer
2. Endometrial histology and biochemistry in climacteric women during oestrogen and progestogen therapy
3. Endometrial disease after treatment with oestrogens and progestogens in the climacteric
4. A prospective 1-year study of estrogen and progestin in postmenopausal women: Effects on the endometrium
5. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone
6. Effects of long term estrogen replacement therapy. II. Neoplasia
7. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study
8. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer
9. Risk of endometrial cancer in relation to oestrogen combined with cyclic progestagen therapy in postmenopausal women
10. Estrogen-progestin replacement therapy and endometrial cancer
11. The role and use of progestogens
12. The endometrial status of women on long-term continuous combined hormone replacement therapy
13. Continuous combined conjugated equine estrogen-progestagen therapy: Effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis
14. Women's opinion on withdrawal bleeding with hormone replacement therapy
15. Compliance considerations with estrogen replacement: Withdrawal bleeding and other factors
16. Barriers for taking long-term hormone replacement therapy: Why do women not adhere to therapy?
17. On menstrual bleeding with hormone replacement therapy
18. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: Influence of bleeding pattern and secretory changes
19. Endometrial status in post-menopausal women on long-term continuous combined hormone replacement therapy (Kliofem). A comparative study of endometrial biopsy, outpatient hysteroscopy and transvaginal ultrasound
20. Pipelle sampling in patients with known endometrial carcinoma
21. Histological sampling of the endometrium: Comparison between formal curettage and the Pipelle sampler
22. Outpatient Pipelle endometrial biopsy in the investigation of post-menopausal bleeding
23. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy
24. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated oestrogens with medroxyprogesterone acetate
25. A simple method for determining the optimal dose of progestin in postmenopausal women receiving oestrogens
26. Endometrial responses to hormone replacement therapy: Histological features compared with those of late luteal phase endometrium
27. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestogen replacement therapy?
28. Can endometrial protection be inferred from the bleeding pattern on combined cyclical hormonal replacement therapy
29. A two-year, double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment
30. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints
31. Comparison of four continuously administered progestogens plus estradiol combinations for climacteric complaints
32. Continuous treatment with a combination of estrogen and gestagen - A way of avoiding endometrial stimulation. Clinical experience with Kliogest®
33. Biochemical studies on the endometrium from postmenopausal women receiving hormone replacement therapy
34. Regulation of estrogen-progestagen receptors in the endometrium
35. Continuous treatment with natural oestrogens and progestagens. A method to avoid endometrial stimulation
36. Combined continuous hormone replacement therapy: A critical review
37. 17 β-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy
38. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy
39. Evaluation of a continuous combined low-dose regimen of estrogenprogestin for treatment of the menopausal patient
40. Hysteroscopic assessment of the effects of a continuous combined oestrogen-progestagen regimen on the endometrium of postmenopausal women
41. Endometrial polyps during menopause: Characterization and significance
42. Tamoxifen and the endometrium: Review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology
43. Hysteroscopy and transvaginal sonography in menopausal women receiving hormone replacement therapy
44. Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestogen therapy in postmenopausal women
45. The behaviour of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients
46. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia
47. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry
48. Endometrial intraepithelial neoplasia (EIN): Will it bring order to chaos? The endometrial collaborative group
49. Endometrial morphology in asymptomatic postmenopausal women
50. Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing treatment for continuous hormones as replacement therapy (CHART2 study)
51. Precursors of corpus carcinoma. Estrogens and adenomatous hyperplasia
52. Granulosa-theca cell tumours and endometrial carcinoma: A study of their relationship and a survey of 80 cases
53. The Stein Leventhal syndrome: Analysis of 43 cases with special reference to association with endometrial carcinoma
54. Association of exogenous estrogen and endometrial carcinoma
55. Increased risk of endometrial carcinoma among users of conjugated estrogens
56. Estrogens and endometrial cancer in a retirement community
57. Increasing incidence of endometrial cancer in the United States
58. Endometrial cancer and estrogen use. Report of a large case-control study
59. Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium
60. Exogenous estrogens and endometrial cancer: A case control study and assessment of potential biases
61. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens
62. Endometrial cancer and patterns of oestrogen replacement therapy
63. Estrogen replacement therapy and the risk of endometrial cancer: Remaining controversies
64. Estrogen replacement therapy and endometrial cancer risk: Unresolved issues
65. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
66. Oestrogen replacement treatment and the risk of endometrial cancer: An assessment of the role of covariates
67. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial
68. Risk of endometrial cancer in relation to use of low-dose, unopposed oestrogens
69. Cancer incidence and mortality in women receiving estrogen and estrogenprogestin replacement therapy - Long term follow-up of a Swedish cohort
70. Risk of endometrial cancer following estrogen replacement with and without progestins
71. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian long cycle study group
72. Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy
73. Long term compliance of continuous combined oestrogen and progestogen replacement in postmenopausal women
74. Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer
75. Accumulated knowledge of Kliogest® safety aspects